comprehensive -WSS

comprehensive

author：fashion 2025-09-30 11:58:31 - browse：4993

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： A public scorecard can help hold safety

WSS

How dance can help nurses traumatized by Covid

Custom gene therapy hints at new path for rare disease treatments

How one patient went off dialysis — and others can too

Why do women spend more than men on medical expenses?

Startup Neumora takes a novel depression drug to Phase 3

Medicare has a new plan to address drug shortages

focus

comprehensive

explore

Medicare details structure of new drug price negotiation program

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Trump demands the U.S. pay no more for drugs than other countries … again

A public scorecard can help hold safety

Duchenne breakthrough therapy leaves behind pioneering families

Kaiser Permanente unions announce official strike date

Malaria cases in Florida and Texas: Here’s what you need to know

How one patient went off dialysis — and others can too

Hollywood unions extend contract negotiations for actors

How dance can help nurses traumatized by Covid

focus

Why do women spend more than men on medical expenses?

FDA advisers vote against ALS treatment from BrainStorm

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Researchers use wearables data and AI to predict preterm birth risk

Did you have Obamacare on your GOP debate bingo card?

Group opposing PBM reform sets lobbying record

leisure time

leisure time

focus

entertainment